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BACKGROUND Paget disease was first described
in 1877 by Sir James Paget. It is a focal disorder of
bone remodelling, involving increased bone
resorption and formation. The aetiology is
uncertain but both environmental and genetic
factors are thought to be involved in pathogenesis.
OBJECTIVE This article outlines the clinical
presentation, diagnosis and treatment of Paget
disease.
DISCUSSION Paget disease is associated with
musculoskeletal pain, significant disability and
impaired quality of life. Complications include
pathological fracture, arthritis in adjacent joints,
hearing loss, other neurological complications,
heart failure and, rarely, osteosarcoma. Recent
clinical trial data has demonstrated histological
and radiological improvements in bone of patients
treated with bisphosphonates. There is little data
evaluating the long term effect of therapy on the
risk of complications, however, restoration of
normal bony architecture offers the prospect that
complications related to deformity and increased
bone fragility might be reduced by effective
therapy.
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Case history
Mr HTC, a retired tiler/plasterer was referred in December
1991 because of pain, localised to the right lower leg.
There was no other pain referable to the skeleton. He
reported a past history of gout affecting the right ankle
beginning in 1976, hypertension and gastro-oesophageal
reflux. On examination, the right lower tibia was warm
and there was some mild swelling at the right ankle but no
obvious deformity. The remainder of the physical exami-
nation was unremarkable. A bone scan demonstrated
increased uptake, consistent with Paget disease (PD) of
bone in the right tibia (Figure 1). Serum alkaline phos-
phatase was 294 U/L (reference range 20–120 U/L) and
urine hydroxyproline excretion was increased, 119
mmoL/2 hour (reference range 0.40–1.92 mmoL/2 hour).
A plain radiograph of the right tibia showed bowing, corti-
cal thickening and disruption of the normal trabelcular
pattern – typical of PD of bone (Figure 2a).
The patient was lost to follow up when he moved inter-
state and remained untreated in spite of a recommendation
to commence bisphosphonate therapy. In June 2003 he
sustained a pathological fracture through the distal third of
the right tibia (Figure 2b) after a fall from standing height
and was treated with an intramedullary nail.
Comment 
Treatment with a bisphosphonate would have been likely
to improve Mr HTC’s symptoms, but whether his fracture
could have been prevented by earlier treatment of PD is
less clear. Caution with the use of oral bisphosphonates is
required with a history of gastroesophageal reflux.
Treatment with intravenous disodium pamidronate
would be an alternative. Open reduction and internal fix-
ation of fractures associated with PD may be required
because of the increased risk of delayed union.
Paget disease (PD) is a common, focal bone remodelling
disorder involving both increased bone resorption and for-
mation. The affected bone is enlarged, disorganised in
structure, and weakened. Paget disease has an esti-
mated prevalence of between 2–6% in the United
Kingdom and a slight male predominance.1,2 Recent
reports suggest that the incidence of PD may be decreas-
ing.3–6 On average three skeletal sites are affected7 with
monostotic disease occurring in 67% of cases.8
Aetiology 
The aetiology of PD of bone remains unclear but geo-
graphical and familial clustering of PD suggests that
common environmental or genetic factors may be
involved in its pathogenesis.1,9,10 A viral aetiology has been
proposed based on observations of virus-like nuclear
inclusions in osteoclasts from pagetic bone, supported by
immunohistochemistry and insitu hybridisation data.11–13
Transduction of normal osteoclast precursor cells with
vectors expressing measles virus nucleocapsid and
matrix genes can induce a paget phenotype in osteoclast-
like cells.14 In a recent case report, PD has been
transferred from acetabulum to an uninvolved mid femur
site as a result of autologous bone grafting during total
hip arthroplasty.15 Familial clustering lends support to the
genetic hypothesis with an autosomal dominant pattern
of inheritance with variable penetrance being described.16
Among 128 first degree relatives of 35 index cases, 40%
were affected,17 whereas 20% of patients registered in
the New England Registry for Paget Disease of Bone
(NERPDB) report having an effected sibling or parent.7
Linkage to a number of genetic loci suggest that PD is a
genetically heterogeneous disorder, but several of the
mutations reported affect the signalling pathway central
to the regulation of osteoclastogenesis.18 
Diagnosis 
Paget disease should be considered in the differential
diagnosis in any patient with unexplained musculoskele-
tal symptoms. Data from the UK General Practice
Research Database (GPRD) suggests that only a small
proportion of cases are coming to clinical diagnosis.5
Among 2465 general practice patients identified as suf-
fering from PD, 66.7% reported bone pain and
analgesics/nonsteroidal anti-inflammatory drug use was
higher than controls in the year before diagnosis (5.2 vs
2.5 prescriptions per year). Bony deformity or swelling
was present in 9.2% and 13.3% were asymptomatic.5
This contrasts with population based data suggesting
that one-third of patients are asymptomatic at diagnosis.8
In the GPRD, the diagnosis was most often made
by X-rays (85%) and isotope scintigraphy was used in
17.5% of patients.5 A mixed appearance of areas of
osteolysis and sclerosis is characteristic of pagetic
bone. Lytic changes are prominent in early lesions with
the occurrence of flame shaped resorption fronts in
long bones or osteoporosis circumscripta in the skull.
Bone volume may be increased, particularly in the
spine and the shafts of long bones. Progression of
disease within a radiologically involved site may occur
but the involvement of new bony sites is uncommon. 
Radionucleotide bone scans should be performed
at the time of diagnosis. They are a sensitive method
for identifying affected bones and can increase detec-
tion of affected sites by 15–30%. Radionuclide uptake
correlates with symptoms attributable to PD.19 By con-
trast, there appears to be little relationship between
radiological changes in bone and symptoms.20 Among
170 patients with 863 pagetic sites only 30% of bones
involved were associated with symptoms.21
An increase in serum alkaline phosphatase is a valu-
able clue to diagnosis22 and the prevalence of
‘biochemical PD’ is reported to be comparable to that
observed in a radiological survey.6 Approximately 95%
of patients have raised serum alkaline phosphatase that
correlates with the extent of skeletal involvement.19,23
Measurement of serum alkaline phosphatase in
patients with unexplained musculoskeletal symptoms
and among family members of patients with PD is
likely to reveal additional cases. 
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Figure 1. Radionuclide bone scan
showing markedly increased uptake
affecting the right tibia
Figure 2. Plain radiographs of the right
tibia demonstrating typical features of
PD (a) at diagnosis and (b) following
the pathological fracture through the
distal third
a b
Complications 
Paget disease is associated with significant disability,
impaired quality of life24 and a variety of complications
(Table 1, Figure 3). Pathological fracture is common.
Among 236 patients followed for a median 10.5 years,
14% of fractures were attributable to PD. In this cohort,
79% of tibia/fibula fractures and 62% of all fractures of the
femur or tibial shaft involved pagetic bone. After the diag-
nosis of PD, the overall incidence of fractures was 8.6 per
100 person years and the incidence of fractures involving
pagetic bone was 1.2 per 100 person years, resulting in a
cumulative incidence of fracture through pagetic bone of
19% at 20 years. Fracture risk was significantly increased
in men but not women. Neither baseline serum alkaline
phosphatase nor number of sites of pagetic involvement
predicted subsequent fracture.8 Patients with a family
history of PD are more likely to report a history of fracture
or deformity.7 Open reduction and internal fixation of frac-
tures has been recommended because delayed union
often complicates fracture healing.25
In the NERPDB, 44% of patients reported reduced
physical activity, 32% were taking chronic pain medica-
tion, and 25% were using a walking aide.7 Arthritis in
joints adjacent to pagetic bone affects up to 50% of
sufferers and deformity 36% of sufferers.25
Neurological complications appear to be relatively
uncommon in general practice settings5 although hearing
loss affected approximately 20% of patients in the
NERPDB.7 Heart failure risk is significantly increased,
whereas the risk for ischaemic heart disease, hyperten-
sion and cerebrovascular events does not differ from
controls.5 Osteosarcoma arising in affected bone is a rare
complication, occurring in 0.3% of GPRD patients.5
Treatment 
Symptomatic disease and preparation for orthopaedic
surgery are the established indications for treatment. 
Symptom control
Bisphosphonates are the treatment of choice and there is
evidence that treatment can improve symptoms, bone histol-
ogy and radiology.26 Calcitonin therapy can also relieve bone
pain and suppresses disease activity.27 In the GPRD, bisphos-
phonate therapy was prescribed for 26.9% of patients and
calcitonin for 7.3%.5 Treatment for 3–6 months with the
potent oral bisphosphonates, alendronate and risedronate,
can normalise bone turnover in 50–60% of patients.26,28 The
potent bisphosphonates suppress bone turnover for 1–2
years before biochemical markers begin to slowly increase
above normal values.29 Continuous treatment with alen-
dronate over a 2 year period has been reported to normalise
the bone scan appearance in approximately one-third of
patients.30 However, among patients with impaired swallow-
ing, significant gastro-oesophageal reflux or oesophageal
motility disorders, these medications should be avoided
because of the risk of erosive oesophagitis and intravenous
preparations such as disodium pamidronate can be used.
Does treatment reduce complications?
There is little data evaluating the long term effect of
Theme: Paget disease of bone – diagnosis and indications for treatment
Reprinted from Australian Family Physician Vol. 33, No. 3, March 2004129
Figure 3. Crude relative rates for common complications of PD of bone
Adapted from: van Staa et al, 2002
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Table 1. Clinical manifestations and
complications of PD
Number of bones involved 3±3
Arthritis 39%
Deformity 36%
Dental complications 7%
Depression 7%
Fracture 14%
Headache 10%
Hearing loss 20%
Joint replacement surgery 9%
Nerve injury 24%
Vision involvement 12%
Other complications 12%
these therapies on the risk of complications. High
dose treatment with etidronate, the first bisphospho-
nate to enter clinical practice, was associated with
mineralisation defects and fracture.31 Other, uncon-
trolled data suggest that etidronate therapy may
reduce the incidence of fracture32 and Melton
reported a nonsignificant reduction in fracture risk
among the minor i ty of pat ients receiv ing any
antipagetic therapy.8 Recent clinical trial data has
demonstrated histological and radiological improve-
ments in bone of pat ients treated with
bisphosphonates26 and offers the prospect that com-
plications related to deformity and increased bone
fragility might be reduced by effective therapy.
Therapy may slow the progression of hearing loss33
and reverse neurological complications.34 An improvement
in bony deformity in a patient with skull and facial involve-
ment has been reported.35 Based on such limited data and
the observation that 62% of patients develop new compli-
cations extended follow up,36 treatment of those regarded
as being of high risk of complications has been advocated.
Paget disease with extensive skull involvement, affecting
weight bearing bones, vertebral bodies and areas adjacent
to major joints, would represent an indication for therapy
under this paradigm. Monitoring of bone turnover, usually
by measurement of alkaline phosphatase at 4–6 monthly
intervals, and re-treatment in those patients in whom nor-
malisation has been achieved when levels increase to
20–25% above the upper limit of normal has been sug-
gested. Among patients whose alkaline phosphatase fails
to normalise re-treatment is suggested when values
increase to 25% above the nadir.37
Conclusion 
Paget disease may be asymptomatic but is frequently
associated with impaired of quality of life and a variety
of complications. Bisphosphonates suppress disease
activity, improve bone histology and radiological appear-
ance. The optimum treatment strategy may be to treat
as early as possible with a view to halting disease pro-
gression. Restoration of normal bone architecture may
be possible with effective suppressive therapy and
offers the potential to reduce complications. However,
whether prolonged suppression of disease activity with
antiresorptive agents will reduce the occurrence of
complications remains to be established.
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